Thomas Harding - Aug 1, 2021 Form 4 Insider Report for Clovis Oncology, Inc. (CLVS)

Role
Senior Vice President and Chief Scientific Officer
Signature
/s/ Thomas C. Harding
Stock symbol
CLVS
Transactions as of
Aug 1, 2021
Transactions value $
-$8,387
Form type
4
Date filed
8/3/2021, 09:38 PM
Previous filing
Jul 6, 2021
Next filing
Sep 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLVS Common Stock Options Exercise +1.56K +90.61% 3.29K Aug 1, 2021 Direct F1
transaction CLVS Common Stock Sale -$3.75K -777 -23.63% $4.82* 2.51K Aug 3, 2021 Direct F2, F3
transaction CLVS Common Stock Options Exercise +1.81K +72.2% 4.32K Aug 1, 2021 Direct F1
transaction CLVS Common Stock Sale -$4.34K -901 -20.84% $4.82* 3.42K Aug 3, 2021 Direct F2, F3
transaction CLVS Common Stock Options Exercise +181 +14.23% 1.45K Aug 1, 2021 By wife F1
transaction CLVS Common Stock Sale -$299 -62 -4.27% $4.82* 1.39K Aug 3, 2021 By wife F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLVS Restricted Stock Units Options Exercise $0 -1.56K -14.29% $0.00 9.38K Aug 1, 2021 Common Stock 1.56K Direct F1, F3, F5
transaction CLVS Restricted Stock Units Options Exercise $0 -1.81K -9.09% $0.00 18.1K Aug 1, 2021 Common Stock 1.81K Direct F1, F4, F6
transaction CLVS Restricted Stock Units Options Exercise $0 -181 -9.08% $0.00 1.81K Aug 1, 2021 Common Stock 181 By wife F1, F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2 Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3 This transaction was executed in multiple trades at prices ranging from $4.82 to $4.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $4.82 to $4.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 On February 1, 2019, the reporting person was granted 25,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
F6 On January 31, 2020, the reporting person was granted 29,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
F7 On January 31, 2020, the reporting person was granted 2,900 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Remarks:

Senior Vice President and Chief Scientific Officer